Indication

Follicular Lymphoma Grade 2

1 clinical trial

1 product

Clinical trial

Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro

Status: Active (not recruiting), Estimated PCD: 2021-11-11

Product